171489-59-1

• 常用中文名：(1R,3R)-1-(1,3-苯并二氧戊环-5-基)-2-(氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚-3-羧酸甲酯
• 常用英文名：Chloropretadalafil
• CAS号：171489-59-1
• 分子式：C₂₂H₁₉ClN₂O₅
• 分子量：426.850
• 发布时间：2019-01-09 09:00:43
• 更新时间：2026-06-29 21:44:24

名称

• 中文名: 顺式-(1R,3R)-1,2,3,4-四氢-1-(3,4-亚甲二氧基苯基)-9H-吡啶并[3,4-B]吲哚-3-羧酸甲酯盐酸盐
• 英文名: (1r,3r)-methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-methylenedioxyphenyl)-9h-pyrido[3,4-b]indole-3-carboxylate
• 中文别名: (1R,3R)-1-(1,3-苯并二氧; 他达拉非中间体三; 他达拉非中间体171-1; (1R,3R)-1-(1,3-苯并二氧戊环-5-基)-2-(氯乙基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-羧酸甲酯; 他达那非中间体3; 他达那非杂质26; 他达中间体3; 他达拉非中间体B; (1R,3R)-1-(苯并[D][1,3]二氧杂环戊烷-5-基)-2-(2-氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-羧酸甲酯; 他达拉非中间体III(杂质III); 1,2,3,4-四氢-2-氯乙酰基-1-(3,4-亚甲基二氧基苯基)-9H-吡啶并[3,4-B]吲哚-3-羧酸-(6R,12aR)-甲酯; 氯丁二烯他达那非; 他达拉非杂质 标准品; 氯乙酰咔啉; 氯乙酰卡琳; 他达拉非TA2 :((1R,3R)-1-(1,3-苯并二氧戊环-5-基)-2-(氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-羧酸甲酯); 他达拉非杂质中间体02; (1R,3R)-甲基 1-(苯并[D][1,3]二氧杂环戊烯-5-基)-2-(2-氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-甲酸酯; 他达那非中间体; 他达拉非杂质TF-4C; 他达那非中间体(甲基氯化物); 他达拉非中间体3; 他达拉非中间体II; 顺式-(1R,3R)-1,2,3,4-四氢-1-(3,4-亚甲二氧基苯基)-9H-吡啶并[3,4-B]吲哚-3-羧酸甲酯盐酸盐(或者甲基氯化物); 叶绿素他达拉非; 甲基氯化物; (1R,3R)-1-(1,3-苯并二氧戊环-5-基)-2-(氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-羧酸甲酯; (1R,3R)-1-(1,3-苯并二氧戊环-5-基)-2-(氯乙酰基)-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-3-羧酸甲酯他达那非中间体(甲基氯化物); 他达那非中间体,(1R,3R)-1-(1,3-苯并二氧戊环-5-基)- 2-(氯乙酰基)-2,3,4,9-四氢-1H-吡啶 并[3,4-B]吲哚-3-羧酸甲酯; 他达那非N-I中间体; 他达拉非氯乙酰杂质; 他达拉非中间体III; 甲基氯化物(他达那非中间体); 1,2,3,4-四氢-2-氯乙酰基-1-(3,4-亚甲基二氧基苯基)-9H-吡啶并[3,4-B]吲哚-3-羧酸-(6R,12-甲酯; 他达拉非N-3中间体; 他达那非N1中间体(甲基氯化物); 他达拉非中间体TDLF-2; 他达拉非N-1中间体; 他达那非N-1中间体; 他达那非甲基氯化物; 他地拉非中间体; 他达拉非杂质01(DSX); 1,2,3,4-四氢-2-氯乙酰基-1-(3,4-亚甲基二氧基苯基)-9H-吡啶并[3,4-B]吲哚-3羧酸-(6R,12-甲脂
• 英文别名: Tadalafil intermediates，(1R,3R)-methyl-1,2,3,4-tetrahydro-2- chloroacetyl-1-(3,4- methylenedioxyphenyl)-9H-pyrido[3,4- B]indole-3-cboxylate; (1R,3R)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-Methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate (Chloropretadalafil); Methyl (1R,3R; (1R,3R)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]"; (6R, 12-methyl 1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4- Tadalafil methylenedioxyphenyl)-9H-pyridol[3,4-b]indole-3- cboxylate; Chloropretadalafil (Methyl (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-p; (1R,3R)-Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-cboxylate; (1R,3R)-1-(3,4-methylenedioxyphenyl)-2-chloroacetyl-2,3,4,9-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; B]indole-3-cboxylate; (1R3R)-METHYL-1,23.4-TETRAHYDRO-2-CHLOROACETL-1-(3.4-METHYLENEDIOXYPHENYL)-9H-PYRIDO[3.4-BJINDOLE-3-CBOXYLATE; (1R,3R)- methyl -1,2,3,4-tetrahydro-1-(3,4- methylenedioxyphenyl)-9H-pyrido [3,4-B]indole-3-cboxyl; (1R,3R)-methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-meth; (1R,3R)-Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; methyl(1R,3R)-1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-cboxylate; Chloropretadalafil (Methyl (1R,3R); (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(chloroacetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-cboxylicacidmethyeste; Tadalafil intermediate 2; (1R,3R)-Methyl 1-(1,3-benzodioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-Pyrido[3,4-b]indole-3-cboxylate; (1R,3R)-1-(1,3-Benzodioxol-5-y)-2-(chloroacetyi)-2,3,4,9-tetrahydro 31H-pyrido(3,4-b]indole-3-cboxyicacid methyl ester; Tadalafil Chloroacetyl Impurity; Methyl (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-β-cboline-3-cboxylate; YL-1-(3,4-METHYLENEDIOXYPHENYL)-9H-PYRIDO[3,4-B]INDOLE-3-CBOXYLATE; 4-b]indole-3-cboxylicacidmethyeste; Intermediate of Tadalafil 3; (6R,12aR)-methyl1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate; (1R,3R)-METHYL-1,2,3,4-TETRAHYDRO-2-CHLOROACETYL-1-(3,4-METHYLENEDIOXYPHENYL)-9H-PYRIDO[3,4-B]INDOLE-3-CBOXYLATE; (6R.12aR)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl1-1(3,4-Methylenedioxyphenyl)9H-pyrido-[3,4-b]-indole-3-Carbxylate; (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic Acid Methyl Ester; (1R,3R)-1-(3,4-methylenedioxyphenyl)-2-chloroacetyl-1,2,3,4-tetrahydro-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; An intermediate in the synthesis of Tadalafil, which is used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor; (1R,3R)-Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3; (1R,3R)-1-(1,3-BENZODIOXOL-5-YL)-2-(CHLOROACETYL)-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B] INDOLE-3-CARBOXYLIC ACID METHYL ESTER; (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-B]indole-3-cboxylic acid methyl ester; (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9- tetrahydro-1H-pyrido[3,4-b]indole-3-cboxylic; (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(chloroacetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylicacidmethyeste; Tadanafil P-1; Chloropretadalafil (Methyl (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-b]indole-3-cboxylate); (6R,12-methyl1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-cboxylate; Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetra-hydro-1H-pyrido[3,4-b]indole-3-cboxylate; (6R.12-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl(3,4-Methylenedioxyphenyl)9H-pyrido-[3,4-b]-indole-3-Cbxylate; Methyl (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylate; (1R,3R)-1-(Benzo[d][1,3]dioxol-5-yl)-2-(2-chloro-acetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-cboxylic acid methyl ester; (1R, 3R) -1- (1,3-benzodioxolane 5-yl) -2- (chloroacetyl) -2,3,4,9-tetrahydro-1H-pyridino [3,4-B] indole-3-cboxylic acid methyl ester; (1R,3R)-1-benzo[1,3]dioxol-5-yl-2-(2-chloroethanoyl)-2,3,4,9-tetrahydro-1H--carboline-3-carboxylic acid methyl ester; TDF-M2; 1H-Pyrido[3,4-b]indole-3-cboxylic acid, 1-(1,3-benzodioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-, methyl ester, (1R,3R); (1R,3R)-1-(1,3-Benzodioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-cboxylic Acid Methyl Ester; 3-Benzodioxol-5-yl)-2-(chloroacetyl-2; (1R,3R)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4-Methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-cboxylate (Chloropretadalafil); Tadalafil IMpurity: IMpurity E; (6R,12AR)-METHYL 1,2,3,4-TETRAHYDRO-2-CHLOROACETYL-1-(3,4-ME - THYLENEDIOXYPHENYL)-9H-PYRIDO-(3,4-B)INDOLE-3-CARBOXYLATE; Tadalafil Chloroacetyle Impurity; (1R,3R)-1-(1,3-BENZODIOXOL-5-YL)-2-(CHLOROACETYL)-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B] INDOLE-3-CBOXYLIC ACID METHYL ESTER; Tadaafil Intermediate; (1R,3R)-Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b; (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(chloroacetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b] indole-3-cboxylic acid methy ester; Tildenafil Impurity 5; adalafil impurity 1

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 627.5±55.0 °C at 760 mmHg
• 熔点: 230-232℃
• 分子式: C₂₂H₁₉ClN₂O₅
• 分子量: 426.850
• 闪点: 333.3±31.5 °C
• 精确质量: 426.098236
• PSA: 80.86000
• LogP: 2.95
• 外观性状: 固体;White to Light yellow powder to crystal
• 蒸汽压: 0.0±1.8 mmHg at 25°C
• 折射率: 1.666
• 储存条件: <0°C;存放于惰性气体之中;避免空气,加热

安全

• 海关编码: 2934999090

合成路线

120-57-0 14907-27-8 79-04-9 ~86% 171489-59-1

文献：INTERQUIM, S.A.; BERZOSA RODRIGUEZ, Xavier; MARQUILLAS OLONDRIZ, Francisco Patent: WO2012/107549 A1, 2012 ; Location in patent: Page/Page column 12 ; WO 2012/107549 A1

14907-27-8 ~% 171489-59-1

文献：Bioorganic and Medicinal Chemistry Letters, , vol. 17, # 3 p. 789 - 792

120-57-0 ~% 171489-59-1

文献：Journal of Medicinal Chemistry, , vol. 46, # 21 p. 4533 - 4542

4299-70-1 ~% 171489-59-1

文献：Journal of Medicinal Chemistry, , vol. 46, # 21 p. 4533 - 4542

1039484-71-3 79-04-9 ~% 171489-59-1 629652-40-0

文献：Bioorganic and Medicinal Chemistry Letters, , vol. 22, # 7 p. 2582 - 2584

749864-17-3 ~% 171489-59-1

文献：Bioorganic and Medicinal Chemistry Letters, , vol. 13, # 8 p. 1425 - 1428

153-94-6 ~% 171489-59-1

文献：RSC Advances, , vol. 4, # 3 p. 1204 - 1211

79-04-9 171596-41-1 ~92% 171489-59-1

文献：Xiao, Sen; Shi, Xiao-Xin; Xing, Jing; Yan, Jing-Jing; Liu, Shi-Ling; Lu, Wei-Dong Tetrahedron Asymmetry, 2009 , vol. 20, # 18 p. 2090 - 2096

上下游产品

上游产品  8
79-04-9 171596-41-1 120-57-0 14907-27-8
4299-70-1 1039484-71-3 749864-17-3 153-94-6
下游产品  3
171596-27-3 171596-29-5 171596-36-4

海关

海关编码	2934999090
中文概述	2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%